Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis

Both pregnant women and newborn infants are vulnerable to group B streptococcal (GBS) infection, but many cases in neonates may be preventable through intrapartum antibiotic prophylaxis. Consensus guidelines established in 1996 proposed using either a risk-based or a screening-based approach to dete...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Obstetrical & gynecological survey 2000-06, Vol.55 (6), p.345-346
Hauptverfasser: Schrag, Stephanie J, Zywicki, Sara, Farley, Monica M, Reingold, Arthur L, Harrison, Lee H, Lefkowitz, Lewis B, Hadler, James L, Danila, Richard, Cieslak, Paul R, Schuchat, Anne
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 346
container_issue 6
container_start_page 345
container_title Obstetrical & gynecological survey
container_volume 55
creator Schrag, Stephanie J
Zywicki, Sara
Farley, Monica M
Reingold, Arthur L
Harrison, Lee H
Lefkowitz, Lewis B
Hadler, James L
Danila, Richard
Cieslak, Paul R
Schuchat, Anne
description Both pregnant women and newborn infants are vulnerable to group B streptococcal (GBS) infection, but many cases in neonates may be preventable through intrapartum antibiotic prophylaxis. Consensus guidelines established in 1996 proposed using either a risk-based or a screening-based approach to determine who should receive prophylaxis. This study examined trends in GBS disease in the years 1993 to 1998. Population-based surveillance was conducted in designated counties of eight states, where project personnel communicated at least twice a month with contacts in participating microbiology laboratories that served acute-care hospitals. GBS infection was diagnosed when the organism was isolated from a nominally sterile site. The criterion age for late-onset neonatal disease was 7 days; for child disease, 90 days; and for adult disease, 15 years. Race-specific incidence rates were estimated using census and live-birth data, and national projections were adjusted for race.A total of 7867 cases of invasive GBS disease were identified in the surveillance areas; 84 percent of isolated were in the blood. Infants less than 3 months of age were affected in 28 percent of cases, and more than two-thirds of these were less than 1 week of age. The proportion of early onset cases identified on the day of birth decreased from 76 percent in 1993 to 71 percent in 1998, not a significant change. Four of five infants with early onset GBS disease presented with bacteremia, another 6 percent with meningitis, and 7 percent with pneumonia. The same case fatality rate of 4 percent was associated with each presentation. Preterm infants (gestational age
doi_str_mv 10.1097/00006254-200006000-00008
format Article
fullrecord <record><control><sourceid>wolterskluwer_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00006254_200006000_00008</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>00006254-200006000-00008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c948-92b070e487da43c1625f336a6036aef48c60b1247e337f3320a4069d4dad203c3</originalsourceid><addsrcrecordid>eNp1kG1LwzAQx4MoWKffIV8gek2yNH0559wGQwX3PmRpSqNdU5KMuW9vt6nvPLgH7u5_HD-EcA73OZTFAwwm6JgTeqoGJ8dCXqAsHzNGSinEJcoAaEkKSeU1uonx47jBOGToZR78rseP-D0F2ydvvDG6xU8uWh0tdh1OjcWzoLGv8bJLQfc6pN0WT7rkNs4nZ_Bb8H1zaPWXi7foqtZttHc_eYTWz7P1dEFWr_PldLIipuSSlHQDBVgui0pzZvLh_5oxoQUMwdZcGgGbnPLCMlYMEwqagygrXumKAjNshOT5rAk-xmBr1Qe31eGgclBHLOoXi_rDcmrJQcrP0r1vkw3xs93tbVCN1W1q1H802TdVt2QZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis</title><source>Journals@Ovid Complete</source><creator>Schrag, Stephanie J ; Zywicki, Sara ; Farley, Monica M ; Reingold, Arthur L ; Harrison, Lee H ; Lefkowitz, Lewis B ; Hadler, James L ; Danila, Richard ; Cieslak, Paul R ; Schuchat, Anne</creator><creatorcontrib>Schrag, Stephanie J ; Zywicki, Sara ; Farley, Monica M ; Reingold, Arthur L ; Harrison, Lee H ; Lefkowitz, Lewis B ; Hadler, James L ; Danila, Richard ; Cieslak, Paul R ; Schuchat, Anne</creatorcontrib><description>Both pregnant women and newborn infants are vulnerable to group B streptococcal (GBS) infection, but many cases in neonates may be preventable through intrapartum antibiotic prophylaxis. Consensus guidelines established in 1996 proposed using either a risk-based or a screening-based approach to determine who should receive prophylaxis. This study examined trends in GBS disease in the years 1993 to 1998. Population-based surveillance was conducted in designated counties of eight states, where project personnel communicated at least twice a month with contacts in participating microbiology laboratories that served acute-care hospitals. GBS infection was diagnosed when the organism was isolated from a nominally sterile site. The criterion age for late-onset neonatal disease was 7 days; for child disease, 90 days; and for adult disease, 15 years. Race-specific incidence rates were estimated using census and live-birth data, and national projections were adjusted for race.A total of 7867 cases of invasive GBS disease were identified in the surveillance areas; 84 percent of isolated were in the blood. Infants less than 3 months of age were affected in 28 percent of cases, and more than two-thirds of these were less than 1 week of age. The proportion of early onset cases identified on the day of birth decreased from 76 percent in 1993 to 71 percent in 1998, not a significant change. Four of five infants with early onset GBS disease presented with bacteremia, another 6 percent with meningitis, and 7 percent with pneumonia. The same case fatality rate of 4 percent was associated with each presentation. Preterm infants (gestational age &lt;37 weeks) with early onset disease were likelier to die than term infants (relative risk, 6.7). Bacteremia and meningitis were the predominant forms of late-onset disease. The overall case fatality rate was 2.8 percent. Early onset neonatal disease dropped from 1993 to 1998, most markedly when the consensus guidelines were released. The reduction was most evident in black neonates. In contrast, the overall rate of late-onset disease changed very little during the period under review. Children aged 3 months to 14 years were about twice as likely to die of GBS disease as were newborn infants with early onset disease. Just over half of affected nonpregnant adults presented with bacteremia, but a wider range of disease was seen in adult than in neonates, including abscess, pericarditis, and necrotizing fasciitis. Invasive GBS disease declined significantly in pregnant girls and women. Bacteremia was most common in this group, accounting for nearly two-thirds of cases. Bacteremic chorioamnionitis and endometritis each occurred in 10 percent of cases, and septic abortion occurred in 7 percent. Adults died significantly more often than newborn infants (relative risk, 2.5).Based on data from 1993, there were an estimated 6100 cases of early onset GBS disease each year before active preventive efforts were under way. In 1998, an estimated 3900 early onset neonatal cases and 200 neonatal deaths were prevented by intrapartum antibiotic prophylaxis. It is hoped that vaccines against GBS ultimately will reduce the need for antibiotic prophylaxis and protect pregnant women.N Engl J Med 2000;342:15–20</description><identifier>ISSN: 0029-7828</identifier><identifier>EISSN: 1533-9866</identifier><identifier>DOI: 10.1097/00006254-200006000-00008</identifier><language>eng</language><publisher>Lippincott Williams &amp; Wilkins, Inc</publisher><ispartof>Obstetrical &amp; gynecological survey, 2000-06, Vol.55 (6), p.345-346</ispartof><rights>2000 Lippincott Williams &amp; Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Schrag, Stephanie J</creatorcontrib><creatorcontrib>Zywicki, Sara</creatorcontrib><creatorcontrib>Farley, Monica M</creatorcontrib><creatorcontrib>Reingold, Arthur L</creatorcontrib><creatorcontrib>Harrison, Lee H</creatorcontrib><creatorcontrib>Lefkowitz, Lewis B</creatorcontrib><creatorcontrib>Hadler, James L</creatorcontrib><creatorcontrib>Danila, Richard</creatorcontrib><creatorcontrib>Cieslak, Paul R</creatorcontrib><creatorcontrib>Schuchat, Anne</creatorcontrib><title>Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis</title><title>Obstetrical &amp; gynecological survey</title><description>Both pregnant women and newborn infants are vulnerable to group B streptococcal (GBS) infection, but many cases in neonates may be preventable through intrapartum antibiotic prophylaxis. Consensus guidelines established in 1996 proposed using either a risk-based or a screening-based approach to determine who should receive prophylaxis. This study examined trends in GBS disease in the years 1993 to 1998. Population-based surveillance was conducted in designated counties of eight states, where project personnel communicated at least twice a month with contacts in participating microbiology laboratories that served acute-care hospitals. GBS infection was diagnosed when the organism was isolated from a nominally sterile site. The criterion age for late-onset neonatal disease was 7 days; for child disease, 90 days; and for adult disease, 15 years. Race-specific incidence rates were estimated using census and live-birth data, and national projections were adjusted for race.A total of 7867 cases of invasive GBS disease were identified in the surveillance areas; 84 percent of isolated were in the blood. Infants less than 3 months of age were affected in 28 percent of cases, and more than two-thirds of these were less than 1 week of age. The proportion of early onset cases identified on the day of birth decreased from 76 percent in 1993 to 71 percent in 1998, not a significant change. Four of five infants with early onset GBS disease presented with bacteremia, another 6 percent with meningitis, and 7 percent with pneumonia. The same case fatality rate of 4 percent was associated with each presentation. Preterm infants (gestational age &lt;37 weeks) with early onset disease were likelier to die than term infants (relative risk, 6.7). Bacteremia and meningitis were the predominant forms of late-onset disease. The overall case fatality rate was 2.8 percent. Early onset neonatal disease dropped from 1993 to 1998, most markedly when the consensus guidelines were released. The reduction was most evident in black neonates. In contrast, the overall rate of late-onset disease changed very little during the period under review. Children aged 3 months to 14 years were about twice as likely to die of GBS disease as were newborn infants with early onset disease. Just over half of affected nonpregnant adults presented with bacteremia, but a wider range of disease was seen in adult than in neonates, including abscess, pericarditis, and necrotizing fasciitis. Invasive GBS disease declined significantly in pregnant girls and women. Bacteremia was most common in this group, accounting for nearly two-thirds of cases. Bacteremic chorioamnionitis and endometritis each occurred in 10 percent of cases, and septic abortion occurred in 7 percent. Adults died significantly more often than newborn infants (relative risk, 2.5).Based on data from 1993, there were an estimated 6100 cases of early onset GBS disease each year before active preventive efforts were under way. In 1998, an estimated 3900 early onset neonatal cases and 200 neonatal deaths were prevented by intrapartum antibiotic prophylaxis. It is hoped that vaccines against GBS ultimately will reduce the need for antibiotic prophylaxis and protect pregnant women.N Engl J Med 2000;342:15–20</description><issn>0029-7828</issn><issn>1533-9866</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNp1kG1LwzAQx4MoWKffIV8gek2yNH0559wGQwX3PmRpSqNdU5KMuW9vt6nvPLgH7u5_HD-EcA73OZTFAwwm6JgTeqoGJ8dCXqAsHzNGSinEJcoAaEkKSeU1uonx47jBOGToZR78rseP-D0F2ydvvDG6xU8uWh0tdh1OjcWzoLGv8bJLQfc6pN0WT7rkNs4nZ_Bb8H1zaPWXi7foqtZttHc_eYTWz7P1dEFWr_PldLIipuSSlHQDBVgui0pzZvLh_5oxoQUMwdZcGgGbnPLCMlYMEwqagygrXumKAjNshOT5rAk-xmBr1Qe31eGgclBHLOoXi_rDcmrJQcrP0r1vkw3xs93tbVCN1W1q1H802TdVt2QZ</recordid><startdate>200006</startdate><enddate>200006</enddate><creator>Schrag, Stephanie J</creator><creator>Zywicki, Sara</creator><creator>Farley, Monica M</creator><creator>Reingold, Arthur L</creator><creator>Harrison, Lee H</creator><creator>Lefkowitz, Lewis B</creator><creator>Hadler, James L</creator><creator>Danila, Richard</creator><creator>Cieslak, Paul R</creator><creator>Schuchat, Anne</creator><general>Lippincott Williams &amp; Wilkins, Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>200006</creationdate><title>Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis</title><author>Schrag, Stephanie J ; Zywicki, Sara ; Farley, Monica M ; Reingold, Arthur L ; Harrison, Lee H ; Lefkowitz, Lewis B ; Hadler, James L ; Danila, Richard ; Cieslak, Paul R ; Schuchat, Anne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c948-92b070e487da43c1625f336a6036aef48c60b1247e337f3320a4069d4dad203c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schrag, Stephanie J</creatorcontrib><creatorcontrib>Zywicki, Sara</creatorcontrib><creatorcontrib>Farley, Monica M</creatorcontrib><creatorcontrib>Reingold, Arthur L</creatorcontrib><creatorcontrib>Harrison, Lee H</creatorcontrib><creatorcontrib>Lefkowitz, Lewis B</creatorcontrib><creatorcontrib>Hadler, James L</creatorcontrib><creatorcontrib>Danila, Richard</creatorcontrib><creatorcontrib>Cieslak, Paul R</creatorcontrib><creatorcontrib>Schuchat, Anne</creatorcontrib><collection>CrossRef</collection><jtitle>Obstetrical &amp; gynecological survey</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schrag, Stephanie J</au><au>Zywicki, Sara</au><au>Farley, Monica M</au><au>Reingold, Arthur L</au><au>Harrison, Lee H</au><au>Lefkowitz, Lewis B</au><au>Hadler, James L</au><au>Danila, Richard</au><au>Cieslak, Paul R</au><au>Schuchat, Anne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis</atitle><jtitle>Obstetrical &amp; gynecological survey</jtitle><date>2000-06</date><risdate>2000</risdate><volume>55</volume><issue>6</issue><spage>345</spage><epage>346</epage><pages>345-346</pages><issn>0029-7828</issn><eissn>1533-9866</eissn><abstract>Both pregnant women and newborn infants are vulnerable to group B streptococcal (GBS) infection, but many cases in neonates may be preventable through intrapartum antibiotic prophylaxis. Consensus guidelines established in 1996 proposed using either a risk-based or a screening-based approach to determine who should receive prophylaxis. This study examined trends in GBS disease in the years 1993 to 1998. Population-based surveillance was conducted in designated counties of eight states, where project personnel communicated at least twice a month with contacts in participating microbiology laboratories that served acute-care hospitals. GBS infection was diagnosed when the organism was isolated from a nominally sterile site. The criterion age for late-onset neonatal disease was 7 days; for child disease, 90 days; and for adult disease, 15 years. Race-specific incidence rates were estimated using census and live-birth data, and national projections were adjusted for race.A total of 7867 cases of invasive GBS disease were identified in the surveillance areas; 84 percent of isolated were in the blood. Infants less than 3 months of age were affected in 28 percent of cases, and more than two-thirds of these were less than 1 week of age. The proportion of early onset cases identified on the day of birth decreased from 76 percent in 1993 to 71 percent in 1998, not a significant change. Four of five infants with early onset GBS disease presented with bacteremia, another 6 percent with meningitis, and 7 percent with pneumonia. The same case fatality rate of 4 percent was associated with each presentation. Preterm infants (gestational age &lt;37 weeks) with early onset disease were likelier to die than term infants (relative risk, 6.7). Bacteremia and meningitis were the predominant forms of late-onset disease. The overall case fatality rate was 2.8 percent. Early onset neonatal disease dropped from 1993 to 1998, most markedly when the consensus guidelines were released. The reduction was most evident in black neonates. In contrast, the overall rate of late-onset disease changed very little during the period under review. Children aged 3 months to 14 years were about twice as likely to die of GBS disease as were newborn infants with early onset disease. Just over half of affected nonpregnant adults presented with bacteremia, but a wider range of disease was seen in adult than in neonates, including abscess, pericarditis, and necrotizing fasciitis. Invasive GBS disease declined significantly in pregnant girls and women. Bacteremia was most common in this group, accounting for nearly two-thirds of cases. Bacteremic chorioamnionitis and endometritis each occurred in 10 percent of cases, and septic abortion occurred in 7 percent. Adults died significantly more often than newborn infants (relative risk, 2.5).Based on data from 1993, there were an estimated 6100 cases of early onset GBS disease each year before active preventive efforts were under way. In 1998, an estimated 3900 early onset neonatal cases and 200 neonatal deaths were prevented by intrapartum antibiotic prophylaxis. It is hoped that vaccines against GBS ultimately will reduce the need for antibiotic prophylaxis and protect pregnant women.N Engl J Med 2000;342:15–20</abstract><pub>Lippincott Williams &amp; Wilkins, Inc</pub><doi>10.1097/00006254-200006000-00008</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0029-7828
ispartof Obstetrical & gynecological survey, 2000-06, Vol.55 (6), p.345-346
issn 0029-7828
1533-9866
language eng
recordid cdi_crossref_primary_10_1097_00006254_200006000_00008
source Journals@Ovid Complete
title Group B Streptococcal Disease in the Era of Intrapartum Antibiotic Prophylaxis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T10%3A57%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wolterskluwer_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Group%20B%20Streptococcal%20Disease%20in%20the%20Era%20of%20Intrapartum%20Antibiotic%20Prophylaxis&rft.jtitle=Obstetrical%20&%20gynecological%20survey&rft.au=Schrag,%20Stephanie%20J&rft.date=2000-06&rft.volume=55&rft.issue=6&rft.spage=345&rft.epage=346&rft.pages=345-346&rft.issn=0029-7828&rft.eissn=1533-9866&rft_id=info:doi/10.1097/00006254-200006000-00008&rft_dat=%3Cwolterskluwer_cross%3E00006254-200006000-00008%3C/wolterskluwer_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true